Puma Biotechnology Inc(PBYI) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | 20.41 | EPS (ttm) | 0.52 | Insider Own | 22.35% | Shs Outstand | 51.1M | Perf Week | -6.39% |
| Market Cap | 0.54B | Forward P/E | - | EPS next Y | - | Insider Trans | -1.78% | Shs Float | 40.1M | Perf Month | 6.14% |
| Enterprise Value | 0.46B | PEG | - | EPS next Q | - | Inst Own | 67.63% | Short Float | 11.33% | Perf Quarter | 32.91% |
| Income | 0.03B | P/S | 2.35 | EPS this Y | - | Inst Trans | 2.14% | Short Ratio | 13.74 | Perf Half Y | 40.35% |
| Sales | 0.23B | P/B | 3.89 | EPS next 5Y | - | ROA | 13.78% | Short Interest | 4.54M | Perf YTD | 77.14% |
| Book/sh | 2.71 | P/C | 5.79 | EPS past 3/5Y | - | ROE | 21.97% | 52W High | -8.35% ($11.50) | Perf Year | 104.26% |
| Cash/sh | 1.82 | P/FCF | 13.22 | Sales past 3/5Y | 0.05% 0.29% | ROIC | 18.7% | 52W Low | 130.38% ($4.57) | Perf 3Y | 339.17% |
| Dividend Est. | - | EV/EBITDA | 11.15 | EPS Y/Y TTM | -46.26% | Gross Margin | 74.83% | Volatility(W/M) | 4.11% 4.5% | Perf 5Y | 106.67% |
| Dividend TTM | - | EV/Sales | 1.97 | Sales Y/Y TTM | -2.86% | Oper. Margin | 13.16% | ATR (14) | 0.44 | Perf 10Y | -73.15% |
| Dividend Ex-Date | - | Quick Ratio | 2.64 | EPS Q/Q | 33.3% | Profit Margin | 11.55% | RSI (14) | 54.7 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.91 | Sales Q/Q | 7.75% | SMA20 | 1.94% ($10.34) | Beta | 1.4 | Target Price | $6 |
| Payout | - | Debt/Eq | 0.03 | Earnings | 2026/11/5 | SMA50 | 7.68% ($9.79) | Rel Volume | 0.68 | Prev Close | $10.62 |
| Employees | 179 | LT Debt/Eq | 0.03 | EPS/Sales Surpr. | 300% 6.6% | SMA200 | 33.53% ($7.89) | Avg Volume(3M) | 0.33M | Price | $10.54 |
| IPO | 2012/4/20 | Option/Short | Yes/Yes | Trades | 2842 | Volume | 224,300 | Change | -0.75% |
💊 Puma Biotechnology (PBYI) is a US-based, commercial-stage biopharmaceutical company focused on the development and commercialization of oncology therapeutics. Its key product, NERLYNX (neratinib), is approved by the US Food and Drug Administration (FDA) for the treatment of HER2-positive breast cancer and is being actively marketed, while the company is also advancing its follow-on pipeline, including alisertib and other candidates.
Over the past 1 year, on the higher side
8% below its 1-year high.
Traded less than usual. That is 68% of its average volume.
Next earnings report: November 5
6 days to go.
PBYI makes money exceptionally well
Of every $100 in sales, $13.16 is kept as operating profit.
Tap to view numbers
The price is about the industry average
Counting its debt, for $100 of yearly operating cash you would pay $1,115. Peers typically go for $2,000. Compared with its own 5-year average, it is 96% pricier now.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +106.7%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 67.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #211 of 594 in the industry
Based on market cap of $544M.
DRUG#210 Bright Minds Biosciences Inc $559M PER - PBYI#211 Puma Biotechnology Inc $544M PER 20.4 
VALN#212 Valneva SE ADR $543M PER - 
ENTX#213 Entera Bio Ltd $543M PER - 
ETRA#214 Electra Therapeutics Inc $542M PER - 
FAQ
What kind of company is PBYI?
PBYI belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PBYI?
The market cap of PBYI is approximately $544M, ranking 3,087 within its sector.
What is the P/E ratio of PBYI?
PBYI has a P/E ratio of approximately 20.4x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for PBYI?
PBYI has recorded a 52-week high of $11.50 and a low of $4.57.
